{"id":"W4417011144","doi":"10.1182/blood-2025-1997","title":"Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Adverse effect; Quality of life (healthcare); Clinical trial; Randomized controlled trial; Nilotinib; Myeloid leukemia; Clinical endpoint; Tyrosine-kinase inhibitor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004174964,0.0008095303,0.001765931,0.0004747183,0.0002062171,0.0008885018,0.0006726393,0.0006377043,0.006899661],"category_scores_gemma":[0.002216691,0.0002983817,0.003992618,0.0004842502,0.0003975529,0.0006887623,0.0005461635,0.00169741,0.0006827762],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007611648,"about_ca_system_score_gemma":0.001019233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000748724,"about_ca_topic_score_gemma":0.001544275,"domain_scores_codex":[0.9983495,0.0009225622,0.0001356009,0.0002379957,0.0001732204,0.0001811553],"domain_scores_gemma":[0.99794,0.0005601398,0.0006979128,0.0002516183,0.0001584075,0.0003917749],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9289402,0.003191653,0.02377186,0.0005456649,0.006776764,0.00006638968,0.00003515766,0.001949165,0.004323905,0.0001551936,0.003926134,0.0263179],"study_design_scores_gemma":[0.3913979,0.3425128,0.2200718,0.000260979,0.0142079,0.0004084575,0.0001587436,0.009277764,0.009120135,0.0009651368,0.01150954,0.0001089353],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837648,0.002432002,0.0005915115,0.0003840202,0.00008419513,0.001176246,0.009384986,0.00007607325,0.002106094],"genre_scores_gemma":[0.9893616,0.0006194647,0.0007254013,0.000245311,0.0000937833,0.001255051,0.004454371,0.00001497718,0.003230102],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006899661,"threshold_uncertainty_score":0.02308166,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009302172277035474,"score_gpt":0.2451694386696932,"score_spread":0.2358672663926577,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}